$VIRX
Viracta Therapeutics, Inc.

2019 Q1 Form 10-K Financial Statement

#000156459019006828 Filed on March 07, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 2017 Q4
Revenue $0.00 $237.0K $0.00
YoY Change -100.0% -64.57% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.440M $11.33M $2.760M
YoY Change -27.38% -16.38% -29.77%
% of Gross Profit
Research & Development $3.248M $14.62M $3.670M
YoY Change -18.17% -32.15% -23.86%
% of Gross Profit
Depreciation & Amortization $2.000K $9.000K $0.00
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $3.248M $25.95M $6.430M
YoY Change -18.17% -26.05% -26.51%
Operating Profit -$25.71M
YoY Change -25.3%
Interest Expense -$260.0K $1.154M -$280.0K
YoY Change -192.53% -17.34% -40.43%
% of Operating Profit
Other Income/Expense, Net $90.00K $249.0K $90.00K
YoY Change -9.09% -30.25% 800.0%
Pretax Income -$5.860M -$26.62M -$6.620M
YoY Change -19.39% -24.94% -22.48%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.860M -$26.62M -$6.620M
YoY Change -19.43% -24.94% -22.48%
Net Earnings / Revenue -11229.96%
Basic Earnings Per Share -$0.21
Diluted Earnings Per Share -$3.467M -$26.10M -$0.21
COMMON SHARES
Basic Shares Outstanding 67.58M 31.67M
Diluted Shares Outstanding 31.67M

Balance Sheet

Concept 2019 Q1 2018 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $24.80M $13.70M $31.80M
YoY Change -2.36% -56.85% -25.35%
Cash & Equivalents $24.81M $13.70M $26.98M
Short-Term Investments $0.00 $4.800M
Other Short-Term Assets $1.600M $1.500M $1.200M
YoY Change 6.67% 27.12% 100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $26.40M $15.20M $32.93M
YoY Change -1.86% -53.84% -23.77%
LONG-TERM ASSETS
Property, Plant & Equipment $1.200M $10.00K $20.00K
YoY Change -50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $110.0K $1.381M
YoY Change 0.0% -92.03%
Total Long-Term Assets $1.400M $120.0K $1.401M
YoY Change 1300.0% -91.43%
TOTAL ASSETS
Total Short-Term Assets $26.40M $15.20M $32.93M
Total Long-Term Assets $1.400M $120.0K $1.401M
Total Assets $27.80M $15.32M $34.33M
YoY Change 2.96% -55.37% -20.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $900.0K $1.390M $1.697M
YoY Change -10.0% -18.24% -10.68%
Accrued Expenses $3.100M $2.530M $3.800M
YoY Change -6.06% -33.07% -25.49%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $6.000M $7.400M $7.200M
YoY Change -17.81% 2.78% 118.18%
Total Short-Term Liabilities $10.00M $11.32M $12.70M
YoY Change -13.79% -10.73% 16.51%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $700.0K $10.00K $112.0K
YoY Change -90.91% -33.73%
Total Long-Term Liabilities $700.0K $10.00K $112.0K
YoY Change -90.91% -33.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.00M $11.32M $12.70M
Total Long-Term Liabilities $700.0K $10.00K $112.0K
Total Liabilities $10.67M $11.33M $12.79M
YoY Change -8.03% -11.42% -42.39%
SHAREHOLDERS EQUITY
Retained Earnings -$632.9M
YoY Change
Common Stock $3.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $17.09M $3.990M $21.54M
YoY Change
Total Liabilities & Shareholders Equity $27.80M $15.32M $34.33M
YoY Change 2.96% -55.37% -20.52%

Cashflow Statement

Concept 2019 Q1 2018 2017 Q4
OPERATING ACTIVITIES
Net Income -$5.860M -$26.62M -$6.620M
YoY Change -19.43% -24.94% -22.48%
Depreciation, Depletion And Amortization $2.000K $9.000K $0.00
YoY Change 0.0% 0.0%
Cash From Operating Activities -$6.113M -$24.40M -$5.350M
YoY Change -6.67% -32.48% -32.87%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $4.780M -$280.0K
YoY Change -100.0% -83.94% -98.26%
Cash From Investing Activities $0.00 $4.780M -$270.0K
YoY Change -100.0% -83.93% -98.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $10.69M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 17.23M 6.343M 24.66M
YoY Change 8689.8% -74.94% -6.31%
NET CHANGE
Cash From Operating Activities -6.113M -24.40M -5.350M
Cash From Investing Activities 0.000 4.780M -270.0K
Cash From Financing Activities 17.23M 6.343M 24.66M
Net Change In Cash 11.12M -13.28M 19.04M
YoY Change -298.06% -170.19% 753.81%
FREE CASH FLOW
Cash From Operating Activities -$6.113M -$24.40M -$5.350M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$24.40M -$5.350M
YoY Change -32.53% -32.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2017 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
snss:LicenseAndOtherRevenueMember
CY2018 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
snss:LicenseAndOtherRevenueMember
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
67578087
CY2018Q2 dei Entity Public Float
EntityPublicFloat
70737319
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13696000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26977000
CY2017Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
4773000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1183000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
32933000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
113000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
642460000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1381000
CY2018Q4 us-gaap Assets
Assets
15324000
CY2017Q4 us-gaap Assets
Assets
34334000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1393000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1697000
CY2018Q4 snss Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
500000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
633436000
CY2017Q4 snss Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
767000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
943000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1440000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1091000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1570000
CY2017Q4 us-gaap Notes Payable Current
NotesPayableCurrent
7204000
CY2018Q4 us-gaap Liabilities
Liabilities
11331000
CY2017Q4 us-gaap Liabilities
Liabilities
12790000
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
20998000
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
20966000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-7000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-632854000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
21544000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11332000
CY2017 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
669000
CY2018 us-gaap Operating Expenses
OperatingExpenses
25947000
CY2017 us-gaap Operating Expenses
OperatingExpenses
35088000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-25710000
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
139000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
164000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2554000
CY2017 snss Issuance Of Common Stock In Underwritten Offering
IssuanceOfCommonStockInUnderwrittenOffering
15000000
CY2017 snss Issuance Of Preferred Stock And Warrants In Underwritten Offering
IssuanceOfPreferredStockAndWarrantsInUnderwrittenOffering
5000000
CY2017 snss Issuance Of Common Stock Preferred Stock And Warrants In Underwritten Offering Issuance Cost
IssuanceOfCommonStockPreferredStockAndWarrantsInUnderwrittenOfferingIssuanceCost
1500000
CY2017 snss Issuance Of Common Stock Through Equity Facilities Gross Proceeds
IssuanceOfCommonStockThroughEquityFacilitiesGrossProceeds
14468000
CY2018 snss Issuance Of Common Stock Through Equity Facilities Gross Proceeds
IssuanceOfCommonStockThroughEquityFacilitiesGrossProceeds
6068000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34334000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
18000
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
17697
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34291000
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34291000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
237000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-34419000
CY2017 us-gaap Interest Expense
InterestExpense
1396000
CY2018 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
7000
CY2017 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
15000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.75
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
21024000
CY2017 snss Issuance Of Common Stock Preferred Stock And Warrants In Underwritten Offering Net Of Issuance Costs
IssuanceOfCommonStockPreferredStockAndWarrantsInUnderwrittenOfferingNetOfIssuanceCosts
18510000
CY2017 snss Issuance Of Common Stock Through Controlled Equity Offering Facilities Net Of Issuance Costs
IssuanceOfCommonStockThroughControlledEquityOfferingFacilitiesNetOfIssuanceCosts
14179000
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
217000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
24000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3033000
CY2018 snss Adjustments To Additional Paid In Capital Common Stock Preferred Stock And Warrants Issued Net Of Issuance Costs
AdjustmentsToAdditionalPaidInCapitalCommonStockPreferredStockAndWarrantsIssuedNetOfIssuanceCosts
126000
CY2018 snss Issuance Of Common Stock Through Controlled Equity Offering Facilities Net Of Issuance Costs
IssuanceOfCommonStockThroughControlledEquityOfferingFacilitiesNetOfIssuanceCosts
5991000
CY2018 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
83000
CY2017 snss Issuance Of Common Stock Through Equity Facilities Issuance Cost
IssuanceOfCommonStockThroughEquityFacilitiesIssuanceCost
289000
CY2018 snss Issuance Of Common Stock Through Equity Facilities Issuance Cost
IssuanceOfCommonStockThroughEquityFacilitiesIssuanceCost
77000
CY2018 us-gaap Profit Loss
ProfitLoss
-26615000
CY2017 us-gaap Profit Loss
ProfitLoss
-35458000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
2637000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
3033000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9000
CY2018 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
192000
CY2017 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
269000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1063000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1921000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-304000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-174000
CY2018 snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
-267000
CY2017 snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
-667000
CY2018 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-497000
CY2017 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-560000
CY2018 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-622000
CY2017 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-63000
CY2017 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-610000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24404000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36142000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
26000
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
4780000
CY2017 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
29774000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4780000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
29748000
CY2017 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
7615000
CY2017 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
4633000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13877000
CY2018 snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
6040000
CY2017 snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
14179000
CY2018 snss Proceeds From Exercise Of Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfStockOptionsAndStockPurchaseRights
303000
CY2017 snss Proceeds From Exercise Of Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfStockOptionsAndStockPurchaseRights
241000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6343000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25315000
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-13281000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
18921000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8056000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
790000
CY2017 us-gaap Interest Paid Net
InterestPaidNet
1066000
CY2017 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
2268000
CY2018 snss Issuance Of Stock From Vesting Of Restricted Stock Awards
IssuanceOfStockFromVestingOfRestrictedStockAwards
83000
CY2018 us-gaap Stock Issued1
StockIssued1
448000
CY2018 snss Legal Expenses Accrued As Cost Of Equity Financing Net Of Adjustments
LegalExpensesAccruedAsCostOfEquityFinancingNetOfAdjustments
39000
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Significant Estimates and Judgments </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company&#8217;s consolidated financial statements and accompanying notes thereto. Actual results could differ materially from these estimates. Estimates, assumptions and judgments made by management include those related to the valuation of equity and related instruments, revenue recognition, stock-based compensation and clinical trial accounting.</p>
CY2018Q4 us-gaap Notes Payable
NotesPayable
7500000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
562000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
578000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
294000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1434000
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
500000
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
700000
CY2018 us-gaap Common Stock Voting Rights
CommonStockVotingRights
One vote per share
CY2015Q4 snss Proceeds From Issuance Of Common Stock Gross
ProceedsFromIssuanceOfCommonStockGross
26200000
CY2018 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2017 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2018Q4 snss Accrued Outside Service Fees Current
AccruedOutsideServiceFeesCurrent
556000
CY2017Q4 snss Accrued Outside Service Fees Current
AccruedOutsideServiceFeesCurrent
1096000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
251000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
471000
CY2018Q4 us-gaap Interest Payable Current
InterestPayableCurrent
284000
CY2017Q4 snss Other Accruals Current
OtherAccrualsCurrent
3000
CY2018Q4 snss Revenue Participation Right Payment Rate
RevenueParticipationRightPaymentRate
0.0675
CY2018 snss Revenue Participation Right Payment Term
RevenueParticipationRightPaymentTerm
10 years from the date of first commercial sale
CY2018 snss Maximum Term Of Revenue Participation Right Payments
MaximumTermOfRevenueParticipationRightPayments
P10Y
CY2015Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25200000
CY2018 snss Securities Policy Maturity Limit Period
SecuritiesPolicyMaturityLimitPeriod
P24M
CY2018 snss Securities Policy Dollar Weighted Average Maturity Limit Period
SecuritiesPolicyDollarWeightedAverageMaturityLimitPeriod
P12M
CY2018 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2018Q4 snss Investments Denominated In Euros Owned At Fair Value
InvestmentsDenominatedInEurosOwnedAtFairValue
800000
CY2017Q4 snss Investments Denominated In Euros Owned At Fair Value
InvestmentsDenominatedInEurosOwnedAtFairValue
800000
CY2018 snss Measurement Dates Of Fair Market Value For Employee Stock Purchase Plan Purchases
MeasurementDatesOfFairMarketValueForEmployeeStockPurchasePlanPurchases
At the beginning of a 12-month offering period or at the end of one of the two related six-month purchase periods.
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10709000
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15081000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
10845000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
10845000
CY2018Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
10845000
CY2018Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
10845000
CY2017Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
25250000
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
25243000
CY2017Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
20470000
CY2017Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
20470000
CY2017Q4 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
4780000
CY2017Q4 snss Marketable Securities Gross Unrealized Losses
MarketableSecuritiesGrossUnrealizedLosses
7000
CY2018 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0
CY2018 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2017 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M3D
CY2018 us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
0
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2800000
CY2018 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-21132000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-24776000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-5483000
CY2016Q4 snss Proceeds From Issuance Of Common Stock Gross
ProceedsFromIssuanceOfCommonStockGross
27900000
CY2016Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25900000
CY2017Q4 snss Fair Value Of Shares Issuable Under Employee Stock Purchase Plan
FairValueOfSharesIssuableUnderEmployeeStockPurchasePlan
25000
CY2018 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
104099
CY2017 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
87020
CY2018Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
218000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
819000
CY2018Q4 snss Share Based Compensation Arrangement Outstanding Securities
ShareBasedCompensationArrangementOutstandingSecurities
10709000
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11528000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2637000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3033000
CY2017 snss Option Exchange Program Tender Offer Announcement Date
OptionExchangeProgramTenderOfferAnnouncementDate
2017-06-09
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
781505
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
778928
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
543650
CY2017Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
2.62
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
50957
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2000000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1900000
CY2018 us-gaap Dividends Share Based Compensation Cash
DividendsShareBasedCompensationCash
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3532000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1622000
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
49000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
945000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4160000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4160000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2118000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.18
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.20
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.34
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.91
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.66
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.66
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.44
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M18D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y6M18D
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-10682000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26615000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35458000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2018Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.046
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.012
CY2018 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.043
CY2017 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.102
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1769000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1441000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
43000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
57000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1812000
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4200000
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.006
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.010
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.010
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.007
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.159
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
1.272
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-1.516
CY2018 snss Effective Income Tax Rate Reconciliation Provision To Return
EffectiveIncomeTaxRateReconciliationProvisionToReturn
-0.007
CY2018 snss Effective Income Tax Rate Reconciliation Expired No Ls And Research And Development Credits And Carryfowards
EffectiveIncomeTaxRateReconciliationExpiredNOLsAndResearchAndDevelopmentCreditsAndCarryfowards
-0.022
CY2018 snss Effective Income Tax Rate Reconciliation Non Qualified Stock Option Cancellations
EffectiveIncomeTaxRateReconciliationNonQualifiedStockOptionCancellations
-0.029
CY2017 snss Effective Income Tax Rate Reconciliation Non Qualified Stock Option Cancellations
EffectiveIncomeTaxRateReconciliationNonQualifiedStockOptionCancellations
-0.003
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
114254000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
109714000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
14885000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
14520000
CY2018Q4 snss Deferred Tax Assets Capitalized Research Cost
DeferredTaxAssetsCapitalizedResearchCost
6134000
CY2017Q4 snss Deferred Tax Assets Capitalized Research Cost
DeferredTaxAssetsCapitalizedResearchCost
6304000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4002000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4528000
CY2018Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
79000
CY2017Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
83000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
143000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
117000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
139497000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
135266000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
139497000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
135266000
CY2017 snss Unrecognized Tax Benefits Increases Related To Change In Tax Rate
UnrecognizedTaxBenefitsIncreasesRelatedToChangeInTaxRate
271000
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-45100000
CY2017 snss Tax Cuts And Jobs Act Of Change In Tax Rate Deferred Tax Asset And Valuation Allowance Provisional Income Tax Expense Benefit
TaxCutsAndJobsActOfChangeInTaxRateDeferredTaxAssetAndValuationAllowanceProvisionalIncomeTaxExpenseBenefit
53700000
CY2018Q4 snss Indemnification Liabilities Incurred
IndemnificationLiabilitiesIncurred
0

Files In Submission

Name View Source Status
0001564590-19-006828-index-headers.html Edgar Link pending
0001564590-19-006828-index.html Edgar Link pending
0001564590-19-006828.txt Edgar Link pending
0001564590-19-006828-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g0lb5hc4g3yj000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snss-10k_20181231.htm Edgar Link pending
snss-20181231.xml Edgar Link completed
snss-20181231.xsd Edgar Link pending
snss-20181231_cal.xml Edgar Link unprocessable
snss-20181231_def.xml Edgar Link unprocessable
snss-20181231_lab.xml Edgar Link unprocessable
snss-20181231_pre.xml Edgar Link unprocessable
snss-ex1018_218.htm Edgar Link pending
snss-ex211_6.htm Edgar Link pending
snss-ex231_12.htm Edgar Link pending
snss-ex311_14.htm Edgar Link pending
snss-ex312_10.htm Edgar Link pending
snss-ex321_8.htm Edgar Link pending